Stone Warren's Insider Trades & SAST Disclosures
Stone Warren's most recent trade in Neogenomics Inc. was a trade of 5,969 Common Stock done . Disclosure was reported to the exchange on May 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Stone Warren.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neogenomics Inc. | Warren C. Stone | Pres & Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 5,969 | 96,762 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Warren C. Stone | Pres & Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 02 May 2025 | 1,454 | 95,308 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Warren Stone C. | Pres & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 94,518 | 94,518 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Warren Stone C. | Pres & Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 52,687 | 52,687 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Warren Stone C. | Chief Commerical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 143,266 | 143,266 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Warren Stone C. | Chief Commerical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 84,317 | 84,317 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Warren Stone C. | Chief Commerical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 8,443 | 93,265 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Warren Stone C. | Chief Commerical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 8,443 | 16,886 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Warren Stone C. | Chief Commerical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 21 Feb 2025 | 2,472 | 90,793 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Warren Stone C. | Chief Commerical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2025 | 59,382 | 59,382 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Warren Stone | Chief Commerical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Dec 2024 | 6,224 | 84,822 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Warren Stone | Chief Commerical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 9,612 | 19,226 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Warren Stone | Chief Commerical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 9,612 | 100,658 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Warren Stone | Chief Commerical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2024 | 9,612 | 93,387 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Warren Stone | Chief Commerical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.86 per share. | 11 May 2024 | 2,341 | 91,046 (0%) | 0% | 14.9 | 34,787 | Common Stock |
| Neogenomics Inc. | Warren Stone | Chief Commerical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2024 | 29,976 | 29,976 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Warren Stone | Chief Commerical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2024 | 17,908 | 17,908 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Warren Stone | Chief Commerical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2024 | 17,908 | 17,908 | - | - | Performance Stock Unit | |
| Neogenomics Inc. | Warren Stone | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 42,344 | 42,344 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Stone Warren | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 25,330 | 25,330 | - | - | Performance Stock Unit | |
| Neogenomics Inc. | Warren Stone | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 25,329 | 25,329 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Stone Warren | President, Clinical Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 01 Dec 2023 | 5,431 | 83,775 (0%) | 0% | 0 | Common Stock | |
| Neogenomics Inc. | Warren Stone | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 53,969 | 53,969 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Warren Stone | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 28,838 | 28,838 | - | - | Restricted Stock Unit | |
| Neogenomics Inc. | Warren Stone | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 21,204 | 21,204 | - | - | Performance Stock Unit | |
| Neogenomics Inc. | Warren Stone | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2022 | 166,113 | 166,113 | - | - | Stock Option (Right to Buy) | |
| Neogenomics Inc. | Warren Stone | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2022 | 89,206 | 89,206 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges